Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313485092> ?p ?o ?g. }
- W4313485092 abstract "Patients with refractory/relapsed (r/r) acute B lymphocytic leukemia (B-ALL) can achieve complete response (CR) after chimeric antigen receptor T-cell (CAR-T) therapy, but recurrence occurs in the short term. To reduce recurrence and improve survival, CAR-T therapy followed by transplantation is a feasible option. We analyzed the long-term follow-up outcomes and the risk factors for allogeneic hematopoietic stem cell transplantation (allo-HSCT) after CR by CAR-T therapy in this study.A total of 144 patients who underwent allo-HSCT after CAR-T therapy in our hospital were enrolled in this study. Target gene analysis was performed in 137 r/r B-ALL patients receiving allo-HSCT after CR by CAR-T therapy. Among the 137 patients, 87 were evaluated for germline predisposition gene mutations, and 92 were evaluated for tumor somatic gene mutations using NGS. The clinical factors, germline predisposition gene and somatic gene mutations associated with the prognosis of patients receiving transplantation after CAR-T therapy were analyzed using univariate Cox regression. Factors related to disease-free survival (DFS) and overall survival (OS) were analyzed using multivariate Cox regression analysis.In 137 r/r B-ALL patients, the 2-year cumulative incidence of recurrence (CIR), OS and DFS in patients receiving allo-HSCT after CAR-T therapy was 31.5%, 71.4%, and 60.5%, respectively. The 2-year OS and DFS in MRD-negative patients were 80.9% and 69.3%, respectively. Univariate Cox analysis showed that pretransplant MRD positivity, fungal infection, germline EP300 mutation and somatic TP53 mutation were associated with a poor prognosis after transplantation; a TBI-based regimen was a protective factor for survival and recurrence after transplantation. Multivariate Cox regression analysis showed that the TBI-based regimen was an independent protective factor for DFS, fungal infection and MRD positivity were independent risk factors for DFS, and tumor somatic TP53 mutation and germline EP300 mutation were independent risk factors for DFS and OS.Germline EP300 mutation and tumor somatic TP53 mutation are poor prognostic factors for posttransplant recurrence and survival in r/r B-ALL patients achieving CR after CAR-T therapy. The prognostic risk factors should be considered in adjusting treatment strategies to improve the efficacy of clinical diagnosis and treatment." @default.
- W4313485092 created "2023-01-06" @default.
- W4313485092 creator A5001036259 @default.
- W4313485092 creator A5012677271 @default.
- W4313485092 creator A5013836476 @default.
- W4313485092 creator A5014756240 @default.
- W4313485092 creator A5026388826 @default.
- W4313485092 creator A5029502933 @default.
- W4313485092 creator A5038040484 @default.
- W4313485092 creator A5038836690 @default.
- W4313485092 creator A5054199475 @default.
- W4313485092 creator A5062252158 @default.
- W4313485092 creator A5084159177 @default.
- W4313485092 creator A5090819151 @default.
- W4313485092 date "2023-01-04" @default.
- W4313485092 modified "2023-09-30" @default.
- W4313485092 title "CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory/relapsed acute B lymphocytic leukemia: Long-term follow-up results" @default.
- W4313485092 cites W1485389706 @default.
- W4313485092 cites W1784814409 @default.
- W4313485092 cites W1987783969 @default.
- W4313485092 cites W1991358041 @default.
- W4313485092 cites W2026849803 @default.
- W4313485092 cites W2044352858 @default.
- W4313485092 cites W2053278212 @default.
- W4313485092 cites W2099570622 @default.
- W4313485092 cites W2115658580 @default.
- W4313485092 cites W2118796952 @default.
- W4313485092 cites W2119323978 @default.
- W4313485092 cites W2129702476 @default.
- W4313485092 cites W2163186602 @default.
- W4313485092 cites W2170513194 @default.
- W4313485092 cites W2339658711 @default.
- W4313485092 cites W2342423058 @default.
- W4313485092 cites W2379365975 @default.
- W4313485092 cites W2523361297 @default.
- W4313485092 cites W2554756829 @default.
- W4313485092 cites W2602369513 @default.
- W4313485092 cites W2613659662 @default.
- W4313485092 cites W2736263494 @default.
- W4313485092 cites W2774624088 @default.
- W4313485092 cites W2787621143 @default.
- W4313485092 cites W2807317397 @default.
- W4313485092 cites W2905326338 @default.
- W4313485092 cites W2911504656 @default.
- W4313485092 cites W2946419110 @default.
- W4313485092 cites W2946567117 @default.
- W4313485092 cites W2982859960 @default.
- W4313485092 cites W2995728170 @default.
- W4313485092 cites W3004666691 @default.
- W4313485092 cites W3020351562 @default.
- W4313485092 cites W3021616332 @default.
- W4313485092 cites W3030234447 @default.
- W4313485092 cites W3032923102 @default.
- W4313485092 cites W3037601773 @default.
- W4313485092 cites W3105631168 @default.
- W4313485092 cites W3112107652 @default.
- W4313485092 cites W3128544040 @default.
- W4313485092 cites W3131243133 @default.
- W4313485092 cites W3154217117 @default.
- W4313485092 cites W3157306983 @default.
- W4313485092 cites W3211929629 @default.
- W4313485092 doi "https://doi.org/10.3389/fonc.2022.1048296" @default.
- W4313485092 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36686744" @default.
- W4313485092 hasPublicationYear "2023" @default.
- W4313485092 type Work @default.
- W4313485092 citedByCount "0" @default.
- W4313485092 crossrefType "journal-article" @default.
- W4313485092 hasAuthorship W4313485092A5001036259 @default.
- W4313485092 hasAuthorship W4313485092A5012677271 @default.
- W4313485092 hasAuthorship W4313485092A5013836476 @default.
- W4313485092 hasAuthorship W4313485092A5014756240 @default.
- W4313485092 hasAuthorship W4313485092A5026388826 @default.
- W4313485092 hasAuthorship W4313485092A5029502933 @default.
- W4313485092 hasAuthorship W4313485092A5038040484 @default.
- W4313485092 hasAuthorship W4313485092A5038836690 @default.
- W4313485092 hasAuthorship W4313485092A5054199475 @default.
- W4313485092 hasAuthorship W4313485092A5062252158 @default.
- W4313485092 hasAuthorship W4313485092A5084159177 @default.
- W4313485092 hasAuthorship W4313485092A5090819151 @default.
- W4313485092 hasBestOaLocation W43134850921 @default.
- W4313485092 hasConcept C126322002 @default.
- W4313485092 hasConcept C143998085 @default.
- W4313485092 hasConcept C144301174 @default.
- W4313485092 hasConcept C203014093 @default.
- W4313485092 hasConcept C2777408962 @default.
- W4313485092 hasConcept C2911091166 @default.
- W4313485092 hasConcept C38180746 @default.
- W4313485092 hasConcept C50382708 @default.
- W4313485092 hasConcept C71924100 @default.
- W4313485092 hasConcept C88879693 @default.
- W4313485092 hasConcept C90924648 @default.
- W4313485092 hasConceptScore W4313485092C126322002 @default.
- W4313485092 hasConceptScore W4313485092C143998085 @default.
- W4313485092 hasConceptScore W4313485092C144301174 @default.
- W4313485092 hasConceptScore W4313485092C203014093 @default.
- W4313485092 hasConceptScore W4313485092C2777408962 @default.
- W4313485092 hasConceptScore W4313485092C2911091166 @default.
- W4313485092 hasConceptScore W4313485092C38180746 @default.
- W4313485092 hasConceptScore W4313485092C50382708 @default.
- W4313485092 hasConceptScore W4313485092C71924100 @default.